Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Please find attached herewith the Press Release for the Q2 FY 26 Results".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals reported strong Q2 FY26 results with consolidated revenue rising 16% year-on-year to Rs. 1,910 Cr, driven by broad-based growth across segments. EBITDA grew 26% to Rs. 325 Cr with a 17% margin, while Profit After Tax increased 20% to Rs. 185 Cr. US Generics revenue jumped 21% to Rs. 566 Cr and Ex-US International Generics surged 31% to Rs. 392 Cr, while India Branded Business grew 5% to Rs. 639 Cr and the API segment rose 15% to Rs. 261 Cr. The company received 6 ANDA approvals during the quarter (226 cumulative), launched 3 products in the US, and completed the acquisition of Utility Therapeutics to enter the US branded drugs market. R&D investment stood at around 10% of revenue, with focus on injectables, peptides, oral solids, and drug discovery.
Strong double-digit revenue and profit growth, especially in international markets, along with US expansion via the Utility Therapeutics acquisition, is likely to be viewed positively by investors. The beat in EBITDA margins and robust ANDA pipeline support a constructive outlook for the stock in the near term.